ChemoCentryx Inc
NASDAQ:CCXI
ChemoCentryx Inc
Revenue
ChemoCentryx Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
ChemoCentryx Inc
NASDAQ:CCXI
|
Revenue
$37.3m
|
CAGR 3-Years
3%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$54.4B
|
CAGR 3-Years
3%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$27.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$29.5B
|
CAGR 3-Years
5%
|
CAGR 5-Years
4%
|
CAGR 10-Years
5%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$10.2B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
26%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.1B
|
CAGR 3-Years
13%
|
CAGR 5-Years
15%
|
CAGR 10-Years
19%
|
See Also
What is ChemoCentryx Inc's Revenue?
Revenue
37.3m
USD
Based on the financial report for Jun 30, 2022, ChemoCentryx Inc's Revenue amounts to 37.3m USD.
What is ChemoCentryx Inc's Revenue growth rate?
Revenue CAGR 5Y
7%
Over the last year, the Revenue growth was 72%. The average annual Revenue growth rates for ChemoCentryx Inc have been 3% over the past three years , 7% over the past five years .